The Medical Aesthetic company which developed an innovative approach to wrinkle reduction raises $50 million in an initial public offering.

​

TUSTIN, Calif., June 3, 2021 /PRNewswire/ — On Wednesday, May 26, 2021, Sofwave™ Medical made its initial public offering (IPO) on the Tel Aviv Stock Exchange (TASE). Sofwave’s™, rapid market adoption enabled the listing on the Tel Aviv Stock Exchange.  The company managed to raise $50 million at a pre-money valuation of ~$200 million. The IPO was led by Barak Capital Underwriters.

​

Sofwave™ is an emerging leader of energy-based non-invasive skin treatment aesthetic medical devices. The company is one of the only companies in the field of aesthetic medicine that is listed on TASE. The company has developed Synchronous Ultrasound Parallel Beam Technology SUPERBTM, which provides a reduction in fine lines and wrinkles and restoration of skin features, and revitalizes collagen. Sofwave’s product is FDA cleared and has the EU CE mark with sales across the global markets.